Newsroom

Prothena has recently implemented an amendment for the AFFIRM-AL Phase 3 study of birtamimab in Mayo Stage IV AL (light chain) amyloidosis which is currently recruiting patients. Birtamimab is an investigational monoclonal antibody designed to target and clear the abnormal protein (amyloid) that can accumulate and cause organ failure in patients with AL amyloidosis. 

New Drug Application filing anticipated based on positive data from interim analysis

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct.

NTLA-2001: First single-course therapy that potentially halts and reverses ATTR

On track to dose first patient by year-end with a systemically delivered CRISPR/Cas9-based therapy